Study of NGM313 in Obese Participants

• Status: Completed
• Trial end date: 2018-07-17
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaulate the safety, tolerability, and efficacy of NGM313 in obese participants

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NGM Biopharmaceuticals, Inc
• Treatments: Pioglitazone

Criteria

Inclusion Criteria:

• Body mass index (BMI) of 30-43 kg/m2

• Waist circumference > 40 inches in males or > 30 inches in females

• Normal ECG readings

Exclusion Criteria:

• Significant history or clinical manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder

• History of any known Congestive heart failure (CHF)

• History of macrovascular disease